fda glp 1 shortage How Crackdowns Are Affecting GLP-1 Use In 2025 FDA restricts non-approved compounded GLP-1

Safety data comes only from separate use of each compound

Our ability to generate future revenues from product sales depends heavily on our or our collaborators ability to successfully: 36 Our expenses could increase beyond expectations if we are required by the FDA, EMA, the competent authorities of individual EU Member States, or other comparable foreign regulatory authorities to perform preclinical studies or clinical trials in addition to those that we currently anticipate

If you reconstitute your peptide at 9pm but don't dose until 5pm the next day, that's fine

Clothes refuse to fit properly, and buying tall boots becomes impossible

Recent Mergers & Acquisitions (M & A) 2025-2026: Mar 2026: BioMarin Pharmaceutical agreed to acquire rare disease biotech Amicus Therapeutics for $4.8B, strengthening metabolic & rare disease franchise overlap with diabetes-associated disorders Mar 2026: Sanofi entered $2.2B acquisition deal for Dynavax Technologies to expand vaccine and immunometabolic pipeline supporting diabetes-comorbidity therapeutics Jan 2026: Eli Lilly and Company announced acquisition of Ventyx Biosciences for $1.2B, expanding cardiometabolic and diabetes-related pipeline into immunology-linked therapies 2026 (closed/announced): Merck & Co

Servings: 31